Kalbe Farma cancels IDR 500 billion buyback, testing Kalbe Farma stock

Published on 10/20/2026 at 10:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kalbe Farma cancels IDR 500 billion buyback on October 8, 2026. Kalbe Farma stock stood at EUR 0.04 on October 20, 2026, with IDR 31.2 trillion value.

Capital allocation and margins

Kalbe Farma canceled its IDR 500 billion buyback on October 8, 2026.
First-half revenue rose 14.05 percent to IDR 19.48 trillion in 2026.
Kalbe Farma stock traded at EUR 0.04 at 10:36 a.m. CEST at Lang & Schwarz on October 20, 2026.
Market capitalization stood at IDR 31.2 trillion as of October 20, 2026.

Kalbe Farma, ID1000125107, Illustration mit AI erstellt.

Kalbe Farma (ISIN ID1000125107) traded at EUR 0.04 at Lang & Schwarz on October 20, 2026 at 10:36 a.m. CEST. The Indonesian healthcare group had canceled an IDR 500 billion share buyback on October 8, 2026, according to Bintang Bisnis.

Buyback reversal changes the capital story

Kalbe had announced the buyback on September 16, 2026, with purchases initially planned from September 17 through December 17, 2026. The company later canceled the plan, leaving capital allocation and spending priorities as the central investor question, Bintang Bisnis reported.

The same report said Kalbe had initially allocated IDR 1 trillion for capital expenditure in 2026 while reviewing several projects. That makes the canceled buyback more than a shareholder-return detail: it also points to a more cautious use of internal funds.

What do the margin figures show?

Kalbe's first-half revenue rose 14.05 percent year over year to IDR 19.48 trillion in 2026, while distribution and logistics revenue increased 26.62 percent to IDR 7.20 trillion, according to Kontan. Cost of sales grew 20.97 percent to IDR 12.16 trillion, pushing gross profit margin down to 37.56 percent from 41.14 percent in the same period of 2025.

Net income fell 2.74 percent to IDR 1.97 trillion in the first half of 2026. The revenue and profit split leaves Kalbe with a clear operating task: preserve volume growth while containing imported input costs and rebuilding margin.

Three dated milestones for KLBF

On September 16, 2026, Kalbe announced the IDR 500 billion buyback; on October 8, 2026, it canceled the plan; on October 20, 2026, the Lang & Schwarz quote stood at EUR 0.04. The sequence moves the discussion from shareholder returns to operating execution.

Next reporting date

The next earnings report is scheduled for November 3, 2026, according to Investing.com.

Kalbe Farma stock stays in context

Kalbe Farma stock was last quoted at IDR 690 on the IDX on October 20, 2026 at 3:32 p.m. WIB. The company had a market capitalization of IDR 31.2 trillion and a 52-week range of IDR 630.00 to IDR 1,345.00 as of October 20, 2026. Global Banking and Finance identifies Kalbe's ticker as KLBF.JK and its home exchange as the IDX.

Kalbe Farma was trading at EUR 0.04 at Lang & Schwarz on October 20, 2026 at 10:36 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Kalbe Farma stock.